Marc Semigran, M.D.
Chief Development Officer
Marc Semigran, M.D. has served as Chief Development Officer since 2022. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc. and previously served as CMO and Senior Vice President of medical science at MyoKardia through its acquisition by Bristol Myers Squibb in 2020 for $13.1 billion. During his tenure at MyoKardia, Dr. Semigran built and expanded his research and development team in order to execute successful translational and development programs including the advancement of mavacamten for patients with obstructive hypertrophic cardiomyopathy. Prior to entering the biotechnology industry, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as Section Head and Medical Director. Dr. Semigran earned A.B., A.M., and M.D. degrees from Harvard University. He completed his internal medicine residency, cardiology, and heart failure fellowship training at Massachusetts General Hospital.
